Global pMDI Use and the Potential Impact of European PFAS Legislation on Access to These Essential Inhaled Medications Authors: Janwillem W H Kocks, Tim Harrison, John P Bell, Andy Rignall, Mina Khezrian, Omar S Usmani Published: 2026 ABSTRACT AbstractIntroductionMany essential inhaled medicines recommended in guidelines are delivered to the lung via pressurized metered-dose inhalers (pMDIs). Global environmental legislation will lead to phasing out of hydrofluoroalkane propellants currently used in pMDIs, owing to their global warming potential (GWP). Furthermore, the European Chemicals Agency is reviewing proposed legislation to ban per- and polyfluoroalkyl substances (PFAS) on the basis of chemical structure, which could also impact pMDI availability. Here, we estimated pMDI use as a proportion of all inhaler use in 60 countries, spanning six geographical regions, to understand the relevance of any pMDI restrictions to patients and prescribers.MethodspMDI use as a percentage of total inhaler use during 2022 was calculated by country and geographical region using inhaler sales data (a surrogate of use) from the IQVIA Quarterly MIDAS database; inhaler use for the 10-year period from 2013 to 2022 was also evaluated for these regions. Data were compared by individual inhalations. The total patient population living with asthma and/or chronic lower respiratory disease was calculated on the basis of Eurostat (the statistical office of the European Union [EU]) 2019 data and available disease prevalence statistics. Maintenance pMDI utilization was estimated by adjusting for ratio of maintenance pMDI use to total inhaler use.ResultsAcross all countries analyzed, pMDIs accounted for the largest proportion of inhaler use in 2022 (77.3%). In 51 out of 55 countries with available country-level data, pMDIs represented > 50% of total inhaler use. After adjusting for pMDI usage, an estimated 8.1 million EU patients received a maintenance pMDI in 2022, with the greatest proportion in Germany and France.ConclusionspMDIs are vital inhalers for most patients in Europe and around the world. While transitioning to near-zero or low-GWP inhalers, it is essential to avoid unintended consequences from the proposed PFAS ban by safeguarding patient access to this essential device option.Keywords: Asthma, Chronic lower respiratory disease, COPD, Global warming potential, Hydrofluoroolefin-1234ze, Maintenance therapy, Next-generation propellant, Per- and polyfluoroalkyl substances, Pressurized metered-dose inhaler, Propellant Key Summary Points Why carry out the study? Pressurized metered-dose inhalers (pMDIs) represent a cornerstone of therapy used by patients with asthma and/or chronic lower respiratory disease (CLRD; i.e., chronic obstructive pulmonary disease). However, as active ingredients vary across inhaler medications and have different clinical effects, inhaler types should not be switched for nonclinical reasons.All propellants currently used, or in development, in pMDIs may be impacted by environmental legislation either relating to their global warming potential or a potential per- and polyfluoroalkyl substances (PFAS) ban, raising concerns about unintended impacts on patient access.This study aimed to estimate pMDI use as a proportion of total inhaler use in 60 countries, spanning six geographical regions, and to estimate the population of patients with asthma and/or CLRD in Europe currently receiving a pMDI device as maintenance therapy to determine who could be impacted by the proposed European Union PFAS legislation. What was learned from the study? pMDIs are used by a large majority of patients for the management of asthma and/or CLRD across all regions of the world.While transitioning to near-zero or low-GWP inhalers, environmental legislation, particularly restrictions such as the proposed PFAS ban, must be carefully balanced to avoid unintended consequences that could limit access to essential pMDI inhalers and negatively impact patient care decisions. Introduction Many essential medicines recommended in global respiratory disease guidelines and commonly used in obstructive airway diseases are delivered to the lung via pressurized metered-dose inhalers (pMDIs) [1–3]. Currently used pMDIs contain a hydrofluoroalkane (HFA) propellant (also known as a fluorinated gas [4, 5]), which atomizes the drug and excipients into droplets to facilitate their inhalation and delivery into the lung [3]. Environmental regulation relevant to pMDI propellants currently arises from two distinct policy areas: measures addressing greenhouse gas emissions (e.g., the Kigali Amendment and EU F-gas regulation) [6, 7], and proposed restrictions on per- and polyfluoroalkyl substances (PFAS), which are based primarily on chemical structure rather than climate impact [8]. Approved HFA propellants, HFA-134a and HFA-227ea, are above the threshold for phaseout in global environmental legislation owing to their global warming potential (GWP) [4, 9, 10]. To address this, two next-generation propellants with near-zero or low GWP are either in development or are being introduced for use in pMDIs, HFA-152a and HFO-1234ze(E), hereafter referred to as HFO-1234ze, respectively [11–14]. Although HFA-152a has a substantially lower global warming potential than currently used propellants, it remains a hydrofluorocarbon and therefore falls within international hydrofluorocarbon phasedown frameworks (e.g., the Kigali Amendment aimed to reduce production and consumption of HFCs by 80–85% by 2047, and EU F-gas regulation) [6, 7, 15]. Owing to a near-zero GWP and different chemical structure from other hydrofluorocarbons, HFO-1234ze has a carbon footprint similar to that of a dry powder inhaler (DPI) [16] and is the only current propellant to not be included in the GWP phasedown [10, 14]. In May 2025, HFO-1234ze was approved by the United Kingdom Medicines and Healthcare Products Regulatory Agency for use in a budesonide/glycopyrrolate/formoterol fumarate (BGF) triple inhaler therapy for adults with moderate-to-severe chronic obstructive pulmonary disease (COPD), with full transition to use expected by 2030 [14, 17]. The European Chemicals Agency (ECHA) is reviewing newly proposed legislation for a ban on PFAS intended to phase out molecules that are persistent, bioaccumulative, or toxic in the environment [18, 19]. PFAS comprise a broad group of synthetic fluorinated compounds characterized by strong carbon–fluorine bonds, which contribute to their environmental persistence and, for certain compounds, their potential for bioaccumulation and long-term environmental exposure that may have toxic properties in humans and wildlife [8, 18, 20]. However, in the draft PFAS legislation, molecules are defined solely by their chemical structure [8], which brings HFO-1234ze into the scope of the ban even though it does not exhibit the characteristic properties (e.g., environmental persistence, bioaccumulation potential, or toxicity) that make some PFAS concerning [5, 20, 21]. Restrictions in the manufacture and use of pMDIs on the basis of the chemical structure of their propellant risks supply shortages and forced inhaler-regimen switch. A significant number of pMDIs (approximately 349 million) are manufactured in the European Union (EU), and 75% of these devices are exported [22], emphasizing the key role the EU-based industry holds in the global supply chain for pMDI production. The aim of this study was to estimate pMDI use as a proportion of total inhaler use in 60 countries spanning six geographical regions, and to estimate the population of patients with asthma and/or chronic lower respiratory disease (CLRD; i.e., chronic obstructive pulmonary disease) in Europe currently receiving maintenance therapy via a pMDI device therapy in order to contextualize the potential impact of the proposed EU PFAS legislation on patients. Methods Study Design and Data Sources This was a retrospective analysis of global inhaler use based on data from IQVIA MIDAS®. This database maintains medication sales and prescription data, helping to understand medication use and prescribing information across countries [23]. At the time of analysis, medication sales and prescription data were available for 60 countries, and all available data were included in the analysis. Quarterly sales volume data were used as a surrogate for pMDI, DPI, and soft-mist inhaler (SMI) use during 2022. Data were assessed from 60 countries spanning six geographical regions (Europe, North America, Central and South America, Africa, the Middle East, and Asia-Pacific). Inhaler use for the 10-year period from 2013 to 2022 was also evaluated for these six regions. Inhaler sales volume data across all respiratory conditions in European countries were obtained to estimate the number of patients who may be impacted by the proposed PFAS regulation. The total patient population living with asthma and/or CLRD was based on Eurostat (the statistical office of the EU [24]) 2019 data and calculated using available global, regional, and/or country-specific disease prevalence statistics [25]. Eurostat calculates aggregate data for the EU and Eurozone, using data collected by national statistical authorities according to harmonized standards [24]. Data Analyses Data on pMDI use were compared by dose to prevent confounding from device actuation count differences and expressed as a percentage of total inhaler use (pMDI + DPI + SMI) by country and geographical region, where country-level data were available. The total patient population with asthma and/or CLRD receiving treatment was estimated on the basis of the assumption that approximately 70% of patients with a diagnosis were receiving medication [26]. The total asthma and/or patient population with CLRD receiving treatment was adjusted for a concomitant asthma and COPD diagnosis, assuming approximately 30% of patients with COPD also had asthma [27]. Total pMDI utilization among patients with asthma and/or CLRD across European countries was estimated by adjusting the calculated patient population with a maintenance pMDI usage factor, defined as the ratio of maintenance pMDI usage to total inhaler usage in maintenance therapy (excluding rescue medications such as short-acting beta-agonists). Ethical Approval Ethics committee approval was not required for accessing data from IQVIA MIDAS® or the Eurostat database, and the data were not identifiable. All necessary permissions were obtained by AstraZeneca for use of the IQVIA database. IQVIA did not provide any support for the analysis or interpretation of the data. The statements, findings, conclusions, views, and opinions contained and expressed in this manuscript are based, in part, on data obtained under license from IQVIA Ltd. These statements, findings, conclusions, views, and opinions are not necessarily those of IQVIA Ltd. or any of its affiliated or subsidiary entities. Results Inhaler Use in 2022 Across all countries analyzed, pMDIs accounted for the largest proportion of inhaler use (77.3% of total inhaler use). In 51 of the 55 countries with available country-level data, pMDIs represented over 50% of total inhaler use, the exceptions being Finland, Denmark, Sweden, and Japan (Table 1). pMDI use was high across all six geographical regions (Central and South America, 90.6%; North America, 86.6%; Africa, 85.2%; the Middle East, 75.4%; Europe, 71.4%; and Asia-Pacific, 69.7%). In 17 of the 20 European countries analyzed, pMDIs represented the majority of inhaler use (50% of total inhaler use). Of these countries, the highest pMDI use was observed in Ukraine (91.3%), followed by the UK (83.5%) and Ireland (80.0%) (Table 1). In 12 countries, pMDIs represented > 90% of all inhaler use, demonstrating a high reliance on this device type; 4 of these countries were from Asia-Pacific (Hong Kong, Malaysia, Vietnam, and Kazakhstan) and 3 were from South America (Colombia, Peru, and Chile; Table 1). In addition, aggregated use across the Central America group of countries was also > 90% (Table 1). Furthermore, in the five largest EU countries by population (EU5 [France, Germany, Italy, Spain, and Poland]), pMDIs accounted for 69.0% of all inhaler use; of these EU5 countries, the highest pMDI usage was observed in France (72.8%) (Table 1). Table 1Inhaler usea (percentage of doses) in 60 countries spanning six geographical regionsRegionCountrypMDI (%)DPI (%)SMI (%)EuropeUkraine91.38.60.1UK83.515.80.7Ireland80.019.20.8Romania76.821.41.8Croatia73.025.71.3France72.826.11.1Hungary70.727.91.4Spain69.129.01.8Germany68.928.62.5Czech Republic66.731.71.6Italy63.434.52.1Poland62.836.70.5Netherlands62.034.43.6Belgium59.938.91.2Greece57.341.41.3Switzerland56.042.11.9Norway53.643.72.7Finland36.161.32.5Denmark36.861.61.5Sweden22.075.62.4Total EU5b69.029.31.7Regional total71.427.21.4North AmericaUSA89.48.81.8Dominican Republic83.316.70.0Canada76.321.72.0Mexico63.824.311.9Regional total86.611.22.2Centraland South AmericaColombia98.71.20.1Peru98.01.80.1Chile97.62.30.1Central Americac93.36.40.4Brazil89.99.70.5Argentina84.815.20.0Regional total90.69.00.4AfricaMorocco95.84.20.0South Africa90.29.80.0Algeria84.815.20.0Egypt76.923.10.0Regional total85.214.80.0Middle EastJordan93.46.30.3Kuwait91.87.70.5Saudi Arabia86.813.20.0United Arab Emirates79.320.50.2Lebanon78.320.80.9Turkey69.630.40.0Regional total75.424.60.03Asia-PacificHong Kong94.63.81.7Malaysia92.96.50.6Vietnam91.97.80.3Kazakhstan90.77.51.7Thailand88.311.40.3Russian Federation85.014.20.8Australia82.615.91.5Philippines80.218.90.8Indonesia75.723.60.7Singapore68.529.81.7Taiwan66.025.98.1India60.639.40.0Republic of Korea57.438.73.8China50.948.70.4Japan27.767.44.9Regional total69.729.50.9OverallTotal inhaler use77.321.41.2aBased on internal analysis by the authors using IQVIA MIDAS® quarterly sales volume data for 2022 [23], accessed March 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved. Inhaler sales used as surrogate for actual usebEU5 countries include France, Germany, Italy, Spain, and PolandcCentral American countries defined as a subregion by IQVIA: Guatemala, Honduras, El Salvador, Nicaragua, Costa Rica, and Panama. These additional six countries bring the total number of countries analyzed to 60DPI dry powder inhaler, pMDI pressurized metered-dose inhaler, SMI soft-mist inhaler Inhaler usea (percentage of doses) in 60 countries spanning six geographical regions Central and South America aBased on internal analysis by the authors using IQVIA MIDAS® quarterly sales volume data for 2022 [23], accessed March 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved. Inhaler sales used as surrogate for actual use bEU5 countries include France, Germany, Italy, Spain, and Poland cCentral American countries defined as a subregion by IQVIA: Guatemala, Honduras, El Salvador, Nicaragua, Costa Rica, and Panama. These additional six countries bring the total number of countries analyzed to 60 DPI dry powder inhaler, pMDI pressurized metered-dose inhaler, SMI soft-mist inhaler Inhaler Use from 2013 to 2022 by Geographical Region Inhaler dose volume increased globally over the 10-year period from 2013 to 2022 (Fig. 1). Importantly, pMDI use consistently represented the largest proportion of inhaler use during this time, accounting for 76.0–77.3% of all inhaler use over the 10-year period (Fig. 1). Furthermore, pMDI use as a proportion of total inhaler use remained consistently high in all geographical regions from 2013 to 2022 (Fig. 2), with some intraregional variability. From 2013 to 2022, increased pMDI use was observed in Central and South America (from 86.3% to 90.6%) and the Middle East (from 68.7% to 75.4%), while a small decrease was observed in Africa (from 88.8% to 85.2%). Inhaler usea across all geographic regions over a 10-year period (2013–2022), expressed as total doses provided and inhaler type as a proportion of total use (%). aBased on internal analysis using IQVIA MIDAS® quarterly sales volume data for 2013–2022, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved. Inhaler sales used as surrogate for use. DPI dry powder inhaler, pMDI pressurized metered-dose inhaler, SMI soft mist inhaler Inhaler usea by geographical region over a 10-year period (2013–2022), expressed as total doses provided and inhaler type as a proportion of total use (%). aBased on internal analysis using IQVIA MIDAS® quarterly sales volume data for 2013–2022, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved. Inhaler sales used as surrogate for use. DPI dry powder inhaler, pMDI pressurized metered-dose inhaler, SMI soft mist inhaler Estimated Patients in the EU with Asthma and/or CLRD Using pMDIs The population of patients living with asthma or CLRD across the 27 member states of the EU (EU27) was estimated to be 25.4 million and 19.2 million, respectively, in 2022 (Fig. 3). Of these patients, 17.8 and 13.4 million, respectively, were estimated to be receiving treatment for asthma or CLRD. After adjusting for the maintenance pMDI usage factor, an estimated total of 8.1 million EU27 patients living with a respiratory condition used a pMDI device for maintenance therapy as part of their care in 2022 (Fig. 3). Using the reported prevalence for the EU27, in the EU5, an estimated 5.5 million patients received a maintenance pMDI for asthma and/or CLRD in 2022; using country-specific prevalence values, the highest use was in Germany and France (Fig. 3). Patient population estimated to receive a pMDI as part of their respiratory care in European countries in 2022. Based on internal analysis by the authors using IQVIA MIDAS® volume sales data for 2022, accessed March 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved. Inhaler sales used as surrogate for use. CLRD chronic lower respiratory disease, EU27 27 member states of the European Union (Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden), pMDI pressurized metered-dose inhaler Discussion These analyses demonstrate the considerable dependence on pMDI-delivered pharmacotherapy for the management of airway disease (asthma and/or CLRD) in Europe and the rest of the world. Across all countries analyzed, pMDIs accounted for nearly 80% of total inhaler use, with the level of pMDI use being consistently high over a 10-year period from 2013 to 2022. It was estimated that 8.1 million patients across EU27 receiving maintenance treatment for their airway disease utilized a pMDI in 2022. Taken together, these findings emphasize the critical worldwide role that pMDIs play in the treatment of airway diseases. All propellants currently used or in development in pMDIs may be impacted by environmental legislation either relating to their GWP or a potential PFAS ban [4, 9, 10, 18, 19]. Propellants that fall into scope for phaseout owing to GWP are hydrofluorocarbons, including both currently used propellants and HFA-152a [4, 9, 10]. pMDIs represent ~0.03% of global anthropogenic greenhouse gas emissions and are therefore a small but important contributor to greenhouse gas emissions [28]. Development of pMDIs with near-zero or low GWP is a critical step toward reducing the environmental impact of healthcare for respiratory disorders and ensuring the long-term viability of their use. Available evidence indicates that exposure to the active pharmaceutical compounds is comparable when currently used propellants are replaced with near-zero or low GWP next-generation propellants, suggesting that they will be viable replacements in clinical practice [13, 29–31]. Building on this, authors of a recent phase 3 trial concluded that the adverse event profile of BGF delivered via pMDI using HFO-1234ze was similar to that of HFA-134a [32]. Notably, a fixed-dose combination of BGF via pMDI using an NGP received approval for use by UK and EU regulatory authorities in 2025, with other inhaled products (pMDIs) using the HFO-1234ze propellant also planned for regulatory submission [14, 33]. Furthermore, it is essential to maintain multiple therapeutic options for asthma and CLRD to safeguard continuous, effective patient care [34]. This was evident during the switch from chlorofluorocarbon (CFC) to HFA-propellant inhalers, as the HFA formulations were not identical to the original CFC versions (e.g., in delivery characteristics); having multiple equivalent products available aided effective transition and minimized risk of treatment disruption [35]. Proposed PFAS legislation is driven by well-established environmental concerns [18]. Certain PFAS compounds are highly persistent in the environment, and PFAS have demonstrated bioaccumulative and toxic properties in humans and wildlife [8, 18]. Regulatory efforts aim to reduce long-term environmental exposure and prevent further accumulation of persistent fluorinated substances in soil and water systems [18]. The ECHA is reviewing newly proposed legislation for a ban on PFAS to phase out molecules that are persistent, bioaccumulative, or toxic in the environment [18, 19]. In this legislation, PFAS are defined by their chemical structure as a group of synthetic chemicals typically resistant to environmental breakdown, per the Organization for Economic Cooperation and Development (OECD) criteria [8, 20]. Although HFO-1234ze is not persistent in the environment, it falls within the scope of the PFAS restriction proposal because the restriction includes both the parent molecule and its minor atmospheric degradation product, trifluoroacetic acid (TFA), the latter being persistent in the environment [20, 36]. However, available evidence suggests that HFO-1234ze contributes only minimally to environmental TFA formation (2% average global yield; range 0–4%) and that the resulting concentrations are far below ecotoxicological thresholds [5, 20, 21, 37]. Given that some therapies are exclusively available in pMDIs [3] and the high frequency of pMDI use shown in this study, a substantial number of patients could potentially be affected by these legislations. Therefore, it is important that environmental policy proposals consider the potential unintended consequences, including reduced availability of inhaled medicines delivered via pMDIs. An alternative solution proposed to overcome the GWP of pMDIs is routine switching to a DPI [38]. However, evidence indicates that nonclinical, nonconsensual device switching adversely impacts healthcare resource utilization and leads to unpredictable disease outcomes [39, 40]. Implementing an inhaler switch has been proposed to require a median 35 min of clinical time per patient, placing a time burden on both patients and physicians [41]. Nonclinical switching can also harm the patient–physician relationship, especially when switches are nonconsented [39]. Furthermore, device type switch may not be an option for all patients, as those with diminished lung function may find it challenging to undertake quick and deep inspiration to deliver medication with DPI; pMDIs deliver medication regardless of the patient’s inhalation strength [42]. Beyond device-type differences, the drugs in inhalers possess different inherent properties regarding their efficacy, safety, and other features, so they should not be considered interchangeable [43]. Indeed, a recent study in the US Veterans Affairs healthcare system showed that switching patients from a budesonide–formoterol MDI to a fluticasone–salmeterol DPI for treatment of COPD and asthma was associated with increased use of rescue medication and healthcare resources [38]. These findings highlight the importance of considering individual patient needs when making inhaler-regimen decisions. A quality consensus for implementing inhaler-regimen switches in patients with respiratory disease involving global experts from primary and secondary care, and payer and patient respiratory disease groups, emphasized that any inhaler switch should be expert-led and patient-centered, focusing on clinical needs, patient preference, and proper implementation procedures [44]. Ongoing dialogue between clinicians, researchers, and policymakers may help ensure that environmental policy discussions consider the potential implications for patient access to these essential inhaled medicines in Europe and around the world. Several limitations in the analyses should be taken into account when considering these findings. First, the analyses used retrospective data, which were not collected specifically to address the study objectives. Second, sales data used as a surrogate of inhaler use is subject to missing data or miscoding. As a result, actual use could be overestimated. Thirdly, assumptions made to calculate the proportion of patients receiving treatment and those with asthma and/or CLRD overlap were based on published data [26, 27] and thus are prone to the inherent limitations of narrative literature reviews, including selection bias. Finally, conservative assumptions were applied throughout the calculation process, meaning that the estimates provided may underestimate the true population size. We acknowledge that the estimation of maintenance pMDI use is subject to several assumptions, including the treatment rate and the overlap between asthma and COPD diagnoses. Although a formal sensitivity analysis was not performed, we considered potential variation in these parameters using plausible ranges based on literature. Given that pMDIs account for the majority of inhaler use in the countries analyzed, moderate changes in these assumptions would not materially alter our main conclusion—that a substantial proportion of patients with asthma and/or CLRD currently rely on maintenance pMDI therapy. Nonetheless, we recognize that more granular real-world data could further refine these estimations, and future studies may benefit from a formal sensitivity analysis to explore the impact of different parameter ranges. Conclusions pMDIs account for the majority of inhaler use across Europe and globally. These findings indicate that a significant proportion of patients rely on pMDI devices for the management of chronic lower respiratory disease, highlighting the importance of understanding the potential impact of policies and legislation that may affect the availability of these inhalers on the patients who rely on and benefit from these medications. Acknowledgments Medical Writing/Editorial Assistance Medical writing and editorial support, under the direction of the authors, was provided by Asrafizra Kunjang, MPH, and Mira Harris, CMC Connect, a division of IPG Health Medical Communications, and was funded by AstraZeneca, in accordance with Good Publication Practice (GPP 2022) guidelines [45]. Author Contributions All authors made significant contributions to the reported work, whether in the conception, study design, execution, acquisition of data, analysis and interpretation, or all these areas; contributed to the drafting, revising, or critical reviewing of the article; gave final approval of the version to be published; agreed on the submission journal; and agreed to be accountable for all aspects of the work. Specific author contributions to the manuscript are as follows: conceptualization: John P. Bell; data curation: Andy Rignall; formal analysis: John P. Bell and Andy Rignall; funding acquisition: John P. Bell; methodology: Andy Rignall; project administration: Andy Rignall; supervision: John P. Bell; writing—review and editing: Janwillem Kocks, Tim Harrison, John P. Bell, Andy Rignall, Mina Khezrian, and Omar S. Usmani. All authors critically reviewed the manuscript for intellectual content and had final responsibility for the decision to submit for publication. Funding The analyses were funded by AstraZeneca. The journal’s Rapid Service Fee was funded by AstraZeneca. Data Availability All data generated or analyzed during this study are included in this published article as Supplementary Information files. Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Data for studies directly listed on Vivli can be requested through Vivli at www.vivli.org. Data for studies not listed on Vivli can be requested through Vivli at https://vivli.org/members/enquiries-about-studies-not-listed-on-the-vivli-platform. The AstraZeneca Vivli member page is also available, outlining further details: https://vivli.org/ourmember/astrazeneca/. Declarations Conflict of Interest Janwillem Kocks reports grants, personal fees, and nonfinancial support from AstraZeneca, Boehringer Ingelheim, and GSK; grants and personal fees from Chiesi; nonfinancial support from Mundi Pharma; grants from Teva and Valneva (outside the submitted work); and personal fees from ALK-Abello, COVIS Pharma, MSD, and Teva; and holds < 5% shares of Lothar Medtec GmbH and is owner of the General Practitioners Research Institute. Tim Harrison, John P. Bell, Andy Rignall, and Mina Khezrian are employees of AstraZeneca and may hold stock and/or stock options in AstraZeneca. Omar S. Usmani reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, and GlaxoSmithKline; personal fees from Cipla, Covis, Menarini, Mereo Biopharma, Mundipharma, Napp, Novartis, Orion, Sandoz, Takeda, Trudell Medical, and UCB; and grants from Edmond Pharma. Ethical Approval Ethics committee approval was not required for accessing data from IQVIA MIDAS® or the Eurostat database, and the data were not identifiable. All necessary permissions were obtained by AstraZeneca for use of the IQVIA database. IQVIA did not provide any support for the analysis or interpretation of the data. The statements, findings, conclusions, views, and opinions contained and expressed in this manuscript are based, in part, on data obtained under license from IQVIA Ltd. These statements, findings, conclusions, views, and opinions are not necessarily those of IQVIA Ltd. or any of its affiliated or subsidiary entities. References Associated Data Data Availability Statement All data generated or analyzed during this study are included in this published article as Supplementary Information files. Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Data for studies directly listed on Vivli can be requested through Vivli at www.vivli.org. Data for studies not listed on Vivli can be requested through Vivli at https://vivli.org/members/enquiries-about-studies-not-listed-on-the-vivli-platform. The AstraZeneca Vivli member page is also available, outlining further details: https://vivli.org/ourmember/astrazeneca/.